|Description||CZC24832 is the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target- and cell-based profiling of CZC24832 revealed regulation of interleukin-17-producing T helper cell (T(H)17) differentiation by PI3Kγ, thus reinforcing selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases.|
|Synonyms||CZC24832; CZC-24832; CZC 24832|
|Current Developer||Cellzome Ltd.|
CZC24832 is the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target-...
PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhib...
AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
CAL-130 racemate is a novel phosphoinositide 3-kinase (PI3K) inhibitor. It is reported that combined inhibition of PI3Kγ/δ as therapy for T cell acute lymphobla...
This active molecular is the S-configuration isomer of AZD6482. AZD6482 is a selective, ATP competitive PI3Kβ inhibitor and IC50 value is 0.01 μm. Meanwhile, AZ...
GDC-0077 is an orally available and selective PI3K inhibitor (IC50 = 0.038 + 0.003 nM) with > 300-fold selective over other Class I PI3K isoforms. GDC-0077 exer...
BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...
TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...
LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.
PI-103 is a potent, cell-permeable, ATP-competitive inhibitor of phosphatidylinositol 3-kinase (PI3K) family members with selectivity toward DNA-PK, PI3K (p110α...
In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed ...
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. Phase 1.
Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms o...
VPS34 inhibitor 1
VPS34 inhibitor 1 is a potent and selective inhibitor of VPS34 (IC50= 15 nM). Vps34 is a phosphoinositide 3-kinase (PI3K) class III isoform that has attracted m...
SF2523 is a dual inhibitor of phosphatidylinositol 3-kinase and bromodomain-containing protein 4 with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for ...
Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB.It is a Immunomodulator. Phaes I clinical trials for Plaque psoriasis...
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...